TY - JOUR
T1 - Impact of Benzodiazepine Use on Length of Stay and 30-Day ED Visits among Hospitalized Hematopoietic Stem Cell Transplant Recipients
AU - Niazi, Shehzad K.
AU - Iqbal, Madiha
AU - Spaulding, Aaron C.
AU - Wood, Chanel
AU - Manochakian, Rami
AU - Paulus, Aneel
AU - Ailawadhi, Sikander
AU - Brennan, Emily
AU - Kharfan Dabaja, Mohamed A.
AU - Sher, Taimur
N1 - Publisher Copyright:
© Lippincott Williams & Wilkins.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Objectives This study assesses the impact of benzodiazepine (BNZ) use on length of stay (LOS) and 30-day emergency department (ED) visits after hematopoietic stem cell transplant (HSCT). Methods Adult patients (18 years and older) who underwent an allogeneic or an autologous HSCT from 2015 to 2018 at the study site were included. Five multivariable models were used for both allogeneic and autologous HSCT: BNZ-naïve status, diazepam equivalent daily dosage (DEDD; 0 vs any), DEDD (excluding 0), ED visits, and LOS. Results BNZ-naïve autologous HSCT recipients were less likely to use any BNZs in the hospital (odds ratio [OR] 0.07, P < 0.001). If prescribed BNZs, then they used a lesser amount (incidence rate ratio 0.39, P < 0.001). BNZ-naïve autologous HSCT recipients were less likely to experience a 30-day ED visit (OR 0.17, P = 0.009). BNZ-naïve allogeneic HSCT recipients were also less likely to use any BNZ than previous users (OR 0.11, P = 0.014). Patient characteristics influenced BNZ naïvety, DEDD usage, LOS for autologous patients, and BNZ naïvety and DEDD for allogeneic patients. Conclusions BNZ use resulted in increased 30-day ED visits after autologous HSCT. BNZ-naïve recipients were less likely to use BNZs during hospital stays; if they required BNZs, then it was in lower dosages.
AB - Objectives This study assesses the impact of benzodiazepine (BNZ) use on length of stay (LOS) and 30-day emergency department (ED) visits after hematopoietic stem cell transplant (HSCT). Methods Adult patients (18 years and older) who underwent an allogeneic or an autologous HSCT from 2015 to 2018 at the study site were included. Five multivariable models were used for both allogeneic and autologous HSCT: BNZ-naïve status, diazepam equivalent daily dosage (DEDD; 0 vs any), DEDD (excluding 0), ED visits, and LOS. Results BNZ-naïve autologous HSCT recipients were less likely to use any BNZs in the hospital (odds ratio [OR] 0.07, P < 0.001). If prescribed BNZs, then they used a lesser amount (incidence rate ratio 0.39, P < 0.001). BNZ-naïve autologous HSCT recipients were less likely to experience a 30-day ED visit (OR 0.17, P = 0.009). BNZ-naïve allogeneic HSCT recipients were also less likely to use any BNZ than previous users (OR 0.11, P = 0.014). Patient characteristics influenced BNZ naïvety, DEDD usage, LOS for autologous patients, and BNZ naïvety and DEDD for allogeneic patients. Conclusions BNZ use resulted in increased 30-day ED visits after autologous HSCT. BNZ-naïve recipients were less likely to use BNZs during hospital stays; if they required BNZs, then it was in lower dosages.
KW - benzodiazepines
KW - emergency department visit
KW - hematopoietic stem cell transplant
KW - length of stay
UR - http://www.scopus.com/inward/record.url?scp=85142900559&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142900559&partnerID=8YFLogxK
U2 - 10.14423/SMJ.0000000000001481
DO - 10.14423/SMJ.0000000000001481
M3 - Article
C2 - 36455905
AN - SCOPUS:85142900559
SN - 0038-4348
VL - 115
SP - 936
EP - 943
JO - Southern medical journal
JF - Southern medical journal
IS - 12
ER -